Better treatments for bile duct cancer
About John Primrose
Professor John Primrose is a Fellow of the Royal College of Surgeons and is based at the University of Southampton. He heads up a clinical trial investigating how to improve treatment for people with cancer of the bile duct, and he is also researching treatments for bowel cancer.
The BILCAP clinical trial will involve around 360 people with bile duct cancer. All the participants will be treated with surgery. After this half will be given a 24 week course of treatment with a chemotherapy drug called capecitabine. The other half will be closely monitored but will not be treated with the drug.
Professor Primrose and his team will find out which of the two treatments gives the longest survival and also note any side effects of capecitabine. The team will also investigate how each treatment affects quality of life.
The trial will be coordinated from the Cancer Research UK Clinical Trials Unit in Birmingham. If combining surgery with chemotherapy improves survival and does not have unacceptable side effects, it could be adopted as the standard treatment for bile duct cancer in the future.
Investigating bowel cancer treatments
Professor Primrose is also leading on another study which involves collecting liver tissue and blood samples from people with bowel cancer which has spread to the liver. These samples are from participants in the EPOC trial.
The samples will be processed and stored so that researchers can investigate how people respond to different combinations of treatment. The trial will also help researchers find out more about the side effects of the drugs involved.
Other research projects by John Primrose
Funding period: 01 March 2009 to 28 February 2014
Funding period: 01 May 2005 to 30 April 2014
Funding period: 01 July 2009 to 30 June 2013
CRUK/06/031: New Epoc B: A exploratory study to investigate the optimal scheduling of chemotherapy in patients with operable colorectal liver metastases (funded by the Bobby Moore Fund for Cancer Research UK)
Funding period: 01 February 2011 to 31 January 2013
CRUK/06/031: New EPOC: peri-operative chemotherapy in patients with resectable colorectal liver metastases - does the addition of an anti-EGF receptor antibody improve progression free survival? (funded by the Bobby Moore Fund)
Funding period: 01 August 2006 to 31 December 2017
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Haemangioblast commitment is initiated in the primitive streak of the mouse embryo